“Need to Know” – Visante’s Series of Key Takeaways for HRSA Grantees

SPONSORED CONTENT by Kristin Fox-Smith and William Wood, Visante

Those of us actively engaged in the 340B Program are well aware of the scores of issues faced by participating hospitals and it’s not surprising since they account for an exceptionally large percentage of all HRSA audits. But, what about other types of Covered Entities (CEs), such as the Specialty Clinics and Grantees? These

Read More »

Spring Cleaning: Three Priorities for Tending to Your 340B Program

SPONSORED CONTENT by Madeline Wallack

A highly contagious novel virus, unprecedented demands on providers, new federal programs and funding, losses on preventative care and elective surgeries, and crazy supply shortages. To say that the last year has been overwhelming on 340B entities is a serious understatement.

Like any phase in life where the objective is survival, program maintenance and “busy work” falls by the wayside.  Unfortunately, 340B

Read More »

Podcast: Dynamics of 340B Program Spotlight the Value of Strong Pharmacy-Finance Partnerships


The devastating double-whammy of Medicare Part B payment cuts and COVID-19 has again highlighted the 340B program’s significance to hospital finance. Once relegated to the hospital’s basement pharmacy, the 340B program is increasingly a topic of boardroom and C-suite discussions.

In the latest episode of Omnicell’s The Future of Pharmacy podcast, learn how health systems can leverage a vibrant, pharmacy-finance partnership to drive successful

Read More »

State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing

Eli Lilly and AstraZeneca are the latest drug makers to disclose that they have been subpoenaed by Vermont's top law enforcement official for documents and information about their participation in 340B. | Shutterstock
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
Read More »

Key Factors To Consider To Ensure Effective Management of a 340B Pharmacy Program


It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs.  Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit.  In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate their program. If your Covered Entity is taking a fresh

Read More »

Webinar: Strategies to Protect 340B and Ensure Access to Vital Health Care, Wed., April 28, 3 PM ET


Please join us for a conversation about why protecting the 340B program is critical to ensuring patient access to health care as well as a legislative update on what’s happening with manufacturers and contract pharmacies, discriminatory reimbursement, and state carve outs.

Learn how Covered Entities can advocate on behalf of themselves and their patients and the tools necessary to support your advocacy efforts. Our hope

Read More »

Optimizing 340B Savings Through Referral Capture

25% – 35%
of a hospital’s contract pharmacy opportunity lies in referral prescriptions

There are several ways to enhance, boost, and optimize 340B savings. This white paper looks at how capturing referrals can benefit a covered entity’s 340B program savings and mission.


According to HRSA guidelines, a covered entity may send a patient to an outside clinic not registered with 340B and consider the patient 340B-eligible only if that patient receives care from a

Read More »

Women in 340B – March 30th at 3PM ET – Webinar Sponsored by Community Voices for 340B


Please join our panel of four exceptional leaders, at the forefront of 340B, as they discuss the impact of women in 340B. The event is hosted by Community Voices for 340B (CV-340B).  We will dive into the program’s history, the amazing women who are currently shaping the program, and why 340B disproportionately impacts women as beneficiaries.

Join us – you won’t want to miss this!

Read More »
Generic selectors
Exact matches only
Search in title
Search in content

Sign up for news summaries and alerts from 340B Report